BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 16164395)

  • 1. Protective effects of angiotensin II interruption: evidence for antiinflammatory actions.
    Dagenais NJ; Jamali F
    Pharmacotherapy; 2005 Sep; 25(9):1213-29. PubMed ID: 16164395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Weber MA
    Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is the role of angiotensin-receptor blockade in cardiovascular protection?
    Cohn JN
    Am Heart J; 2006 Nov; 152(5):859.e1-8. PubMed ID: 17070145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Renin-angiotensin system modulation: instructions for use].
    Bellis A; Rozza F; Crispo S; Trimarco B
    G Ital Cardiol (Rome); 2008 Feb; 9(2):79-89. PubMed ID: 18383770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antiinflammatory action of angiotensin receptor blocker].
    Katagiri T; Takei M; Sakurai M; Matsuyama T; Sakai T
    Nihon Rinsho; 2006 Jul; 64 Suppl 5():506-11. PubMed ID: 16895219
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
    Krum H; Gilbert RE
    J Hypertens; 2007 Jan; 25(1):25-35. PubMed ID: 17143168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension.
    Tocci G; Sciarretta S; Facciolo C; Volpe M
    Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):767-76. PubMed ID: 17605654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-diabetic effect of blockade of the renin-angiotensin system.
    Ando K; Fujita T
    Diabetes Obes Metab; 2006 Jul; 8(4):396-403. PubMed ID: 16776746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers.
    Nickenig G; Ostergren J; Struijker-Boudier H
    J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7 Suppl 1():S1-7. PubMed ID: 16969748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes.
    Karalliedde J; Viberti G
    J Hum Hypertens; 2006 Apr; 20(4):239-53. PubMed ID: 16452996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moving beyond angiotensin II to also target aldosterone?
    Little WC; Kirkman PM
    J Am Coll Cardiol; 2009 Aug; 54(6):513-4. PubMed ID: 19643311
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade.
    Dandona P; Dhindsa S; Ghanim H; Chaudhuri A
    J Hum Hypertens; 2007 Jan; 21(1):20-7. PubMed ID: 17096009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II type 1 receptor as a novel therapeutic target in rheumatoid arthritis: in vivo analyses in rodent models of arthritis and ex vivo analyses in human inflammatory synovitis.
    Price A; Lockhart JC; Ferrell WR; Gsell W; McLean S; Sturrock RD
    Arthritis Rheum; 2007 Feb; 56(2):441-7. PubMed ID: 17265479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin receptor blockers and cardiovascular protection: are we ONTARGET?
    Ram CV; Deedwania PC
    Am J Cardiol; 2008 Nov; 102(9):1281-3. PubMed ID: 18940307
    [No Abstract]   [Full Text] [Related]  

  • 18. Angiotensin receptor blockers: current status and future prospects.
    Kumar S; Ram CV
    Indian Heart J; 2007; 59(6):443-53. PubMed ID: 19151457
    [No Abstract]   [Full Text] [Related]  

  • 19. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP
    Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effects of renin-angiotensin blockade beyond blood pressure control.
    Mancia G; Giannattasio C; Seravalle G; Quarti-Trevano F; Grassi G
    J Hum Hypertens; 2009 Sep; 23(9):570-7. PubMed ID: 19190657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.